Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
Phase 1
44
about 4 years
18+
Male only
1 site in CA
About this study
This trial is testing whether adding Pedmark to standard cisplatin chemotherapy reduces ear damage (ototoxicity) in men with stage II-III metastatic testicular germ cell tumors. The goal is to see if Pedmark can help protect hearing during treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cisplatin
- 2.Take Sodium Thiosulfate Anhydrous
- 3.Undergo Audiometric Test
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), Antidotes, Deterrents, and Toxicologic Agents (Chelating Activity)
injection, intravenous, injection (Injection)
Secondary: Incidence of adverse events (AEs), Progression-free survival (PFS)
imaging
Oncology